By Adam Feuerstein, TheStreet.com Senior Columnist
THESTREET.COM — 09/30/09
BOSTON (TheStreet) -- A calendar of important, potentially stock-moving biotech events for October:
Oct. 5-6
JMP Securities Healthcare Focus conference
Oct. 7-8
Cowen & Co. 12 th Annual Therapeutics Conference
Oct. 8
FDA approval decision date for Spectrum Pharmaceuticals' (Symbol: SPPI) colon cancer drug Fusilev.
Oct. 13
Presentation at the American Neurological Association meeting of detailed data from the phase III study of Avanir Pharmaceuticals' (Symbol : AVNR) Zenvia, an experimental drug for the treatment of uncontrollable laughing and crying episodes a condition known medically as pseudobulbar affect. Avanir announced positive top-line results from this study in August.
Third-quarter earnings: Johnson & Johnson (Symbol : JNJ) (before market open) and Gilead Sciences (Symbol : GILD) (after market close.)
Oct. 14
The FDA'sPeripheral and Central Nervous System Drug Advisory Committee will convene to review Acorda Therapeutics' (Symbol : ACOR) fampridine (brand name Amaya). The proposed indication for Amaya is to improve the walking ability of patients with multiple sclerosis. Biogen Idec (Symbol : BIIB) is Acorda's marketing partner for Amaya.
Take note: The FDA's briefing documents for Amaya should be posted to the agency's web site on Oct. 12 or 13. When available, those documents can be found here.
Third-quarter earnings: Abbott Labs (Symbol : ABT) (before market open.)
Oct. 15
Third-quarter earnings: Cubist Pharmaceuticals (Symbol : CBST) (after market closes.)
Oct. 16-21
The American College of Rheumatology annual meeting in Philadelphia. Noteworthy clinical data expected for presentation includes Pfizer's CP-690550 in rheumatoid arthritis and Rigel Pharmaceuticals' (Symbol : RIGL) R788 in rheumatoid arthritis
Oct. 19
FDA approval decision date for Amgen's (Symbol : AMGN) osteoporosis drug denosumab. If approved, Amgen (Symbol : AMGN) will market the drug under the brand name Prolia.
Oct. 22
FDA's approval decision date for Acorda's drug Amaya.
Oct. 24-28
The Obesity Society annual meeting convenes in Washington, D.C. Detailed data from phase III studies of three closely watched weight-loss drugs will be presented at the meeting: Arena Pharmaceuticals' (Symbol : ARNA) lorcaserin, Vivus' (Symbol : VVUS) Qnexa and Orexigen Therapeutics' (Symbol : OREX) Contrave.
Oct. 30
FDA approval decision date for GTX's Acapodene for the reduction of bone fractures in prostate cancer patients undergoing androgen deprivation therapy.
FDA approval decision date for Transcept Pharmaceuticals' (Symbol : TSPT) Intermezzo for insomnia.
Oct. 30-Nov. 4
The American Association for the Study of Liver Disease convenes in Boston. This is the most important meeting for hepatitis C drug research held on the U.S. every year. Stocks to watch include Vertex Pharmaceuticals (Symbol : VRTX), InterMune (Symbol : ITMN), Pharmasset (Symbol : VRUS), Idenix Pharmaceuticals (Symbol : IDIX) and Anadys Pharmaceuticals (Symbol : ANDS).
Important clinical trials with potential data readouts or other biotech events expected in October:
Company: Protalix BioTherapeutics (Symbol : PLX)
Drug/indication: prGCD (Uplyso) in Gaucher's disease.
Company: Allos Therapeutics (Symbol : ALTH)
Commercial launch of Folotyn in peripheral T-cell lymphoma
and Anadys Pharmaceuticals (Symbol : ANDS).
Important clinical trials with potential data readouts or other biotech events expected in October:
Company: Protalix BioTherapeutics (Symbol : PLX)
Drug/indication: prGCD (Uplyso) in Gaucher's disease.
Company: Allos Therapeutics (Symbol : ALTH)
Commercial launch of Folotyn in peripheral T-cell lymphoma
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.